Groupama Asset Management cut its stake in Amgen by nearly 15% in Q4, selling off over 3,000 shares. At quarter’s end, their ...

President Donald Trump’s exemption of pharmaceuticals from “reciprocal” tariffs limited the declines of biopharma stocks as ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

One factor that keeps some investors away from healthcare stocks is the sector's dearth of generous and reliable dividend payers. This stands to reason, as nearly every stage of drug development and ...

In a report released on April 3, Gregory Renza from RBC Capital maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.

Explore the top-performing Nasdaq 100 stocks this year as the index moves into a technical bear market this year.

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

The latest trading session saw Amgen (AMGN) ending at $310.09, denoting a +1.44% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 4.84%. On the ...

Select stocks may be just fine despite tariffs and the economic damage they could cause. The S&P 500 plummeted 4.8% Thursday ...

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on ...

Amgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval ...